Stock Chart

RPRX

$70.01 +0.81%
Score: 36.2 EXTENDED
LEAPs: SELL $48
i
LEAPs Option Signal

Type: SELL growth_1yr
Strike: $48
Premium: $2.60
Expiry: Dec 18, 2026
Target: $46
Score: -100

LEAPs are long-term options (1+ year) with less time decay.
Pro
Screener
Vol: 1.02x (vs SPY: 1.4x | vs QQQ: 1.2x)
Volume Ratio Explained

Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech

Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity

Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Chart Pattern · as of Nov 11, 2026
Rising Wedge weak / forming — below our quality gate quality 50/100
A Rising Wedge is taking shape but hasn't passed our quality gate (60/100), so no projected path or levels are shown — only the forming rails on the chart below.
Historically breaks down 72% of the time; target hit in 78% of down-breaks (n=653)
Technical Chart
CHART OVERLAYS
Active: 2
INDICATORS
TRENDLINES
OPTIONS FLOW
VOLUME & PRICE
OTHER

About RPRX - Royalty Pharma plc Class A Ordinary Shares

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Key Statistics

Market Cap $40B
P/E Ratio 45.39
Dividend Yield 0.01%

This RPRX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track RPRX's price movements with trendlines, gamma walls, and key support/resistance levels.